BR9205967A - Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória - Google Patents

Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória

Info

Publication number
BR9205967A
BR9205967A BR9205967A BR9205967A BR9205967A BR 9205967 A BR9205967 A BR 9205967A BR 9205967 A BR9205967 A BR 9205967A BR 9205967 A BR9205967 A BR 9205967A BR 9205967 A BR9205967 A BR 9205967A
Authority
BR
Brazil
Prior art keywords
inflammatory arthritis
labeled molecules
interleukin receptor
molecules treatment
treatment
Prior art date
Application number
BR9205967A
Other languages
English (en)
Inventor
Thasia G Woodworth
Jean C Nichols
Patricia A Bacha
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of BR9205967A publication Critical patent/BR9205967A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
BR9205967A 1991-05-03 1992-05-04 Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória BR9205967A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69548091A 1991-05-03 1991-05-03
US87652192A 1992-04-30 1992-04-30
PCT/US1992/003714 WO1992019259A1 (en) 1991-05-03 1992-05-04 Interleukin receptor targeted molecules for treatment of inflammatory arthritis

Publications (1)

Publication Number Publication Date
BR9205967A true BR9205967A (pt) 1994-07-26

Family

ID=27105578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9205967A BR9205967A (pt) 1991-05-03 1992-05-04 Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória

Country Status (7)

Country Link
EP (1) EP0668774A1 (pt)
JP (1) JPH06510750A (pt)
AU (1) AU665763B2 (pt)
BR (1) BR9205967A (pt)
CA (1) CA2108886A1 (pt)
NO (1) NO933960L (pt)
WO (1) WO1992019259A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AR092177A1 (es) 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
MX2016011132A (es) 2014-02-28 2016-12-08 Regeneron Pharma Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
KR102462039B1 (ko) 2016-09-01 2022-11-02 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TW202332696A (zh) 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MX2020004467A (es) 2017-10-30 2020-10-22 Sanofi Biotechnology Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
BR112022000581A2 (pt) 2019-08-05 2022-03-03 Regeneron Pharma Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE448386B (sv) * 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US5080898A (en) * 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
WO1992006117A1 (en) * 1990-09-28 1992-04-16 Seragen, Inc. Inhibiting unwanted immune responses

Also Published As

Publication number Publication date
JPH06510750A (ja) 1994-12-01
WO1992019259A1 (en) 1992-11-12
AU665763B2 (en) 1996-01-18
EP0668774A1 (en) 1995-08-30
NO933960D0 (no) 1993-11-02
AU1992792A (en) 1992-12-21
EP0668774A4 (en) 1995-04-25
NO933960L (no) 1993-12-28
CA2108886A1 (en) 1992-11-04

Similar Documents

Publication Publication Date Title
ID1033B (id) Susunan montasi dengan menggunakan ulir sekerup bentuk kerucut terpancung untuk pipa-pipa
MX9200148A (es) Fabricacion de cuerpos de cordierita
MX9200152A (es) Fabricacion de cuerpos de cordierita
FI935880A0 (fi) Immobiliserade Lewis-syrakatalysatorer
DE69127704T2 (de) Spaltöfen
BR9205967A (pt) Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória
FI935705A0 (fi) Superabsorberande struktur
FI88567B (fi) En generell synkronisk 2n+1 -divisor
FI912575A0 (fi) Ruuvikierrerakenne
BR9607427A (pt) Inibiçao de angiogêne usando interleucina 12
DK206391A (da) Slambehandling
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
NO961747D0 (no) Behandling av reumatoid artritt
MX9102079A (es) Plemezcla de semduramicina
BR9206090A (pt) Fabricação de produtos cerâmicos
NO974956D0 (no) Terapeutisk sammensetning for artritis
DE69212617T2 (de) Offset-Verminderer
KR950018585U (ko) 토건용 골재 이송장치의 콤베어 로울러
KR970016559U (ko) 약품계량용 스크류피더의 구조
ITMI921471A1 (it) Apparecchiatura per la misura della resistivita' del calcestruzzo
DK25792A (da) Teglvaerksprodukter
KR930006833U (ko) 벽돌
DE69128087D1 (de) Monozerstreute einfache und doppelte emulsionen und herstellungsverfahren
FI2141U1 (fi) Arrangemang med foensterluckor
BR8901860A (pt) Jogo do sete

Legal Events

Date Code Title Description
EE Request for examination
FC Decision: refusal
FC Decision: refusal
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/22 (2006.01), A61K 47/64 (2017.0